SECFilings.com helps investors track public company disclosures with smart tools and real-time alerts. Trusted by thousands of investors daily.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Form 8-K - Current report - Item 5.02
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 8-K/A - Current report: [Amend] - Item 5.02 Item 9.01
Form 8-K - Current report - Item 1.01 Item 2.03 Item 8.01 Item 9.01
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 8-K - Current report - Item 5.02 Item 9.01
Form 8-K - Current report - Item 5.03 Item 5.07 Item 9.01
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 8-K - Current report - Item 7.01 Item 8.01 Item 9.01
Form 8-K - Current report - Item 5.02
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Form 8-K - Current report - Item 1.01 Item 8.01 Item 9.01
Form 8-K - Current report - Item 2.02 Item 9.01
Form 8-K - Current report - Item 5.02 Item 9.01
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 8-K - Current report - Item 1.01 Item 2.03 Item 8.01 Item 9.01
Form 8-K - Current report - Item 7.01 Item 9.01
Form S-8 - Securities to be offered to employees in employee benefit plans
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 8-K - Current report - Item 5.02 Item 5.07 Item 9.01
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Form 8-K - Current report - Item 5.03 Item 9.01
Form 8-K - Current report - Item 2.02 Item 9.01
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 8-K - Current report - Item 7.01
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 8-K - Current report - Item 5.02
Form 8-K - Current report - Item 5.02
Form S-8 - Securities to be offered to employees in employee benefit plans
Form 8-K - Current report - Item 5.07 Item 9.01
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 8-K - Current report - Item 7.01 Item 9.01
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Form 8-K - Current report - Item 2.02 Item 9.01
Form 8-K - Current report - Item 2.02
Form 8-K - Current report - Item 5.02
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 8-K - Current report - Item 2.02 Item 8.01 Item 9.01